<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01045681</url>
  </required_header>
  <id_info>
    <org_study_id>IFM2009-01</org_study_id>
    <secondary_id>Eudract 2009-012359-91</secondary_id>
    <nct_id>NCT01045681</nct_id>
  </id_info>
  <brief_title>Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma</brief_title>
  <acronym>BVD</acronym>
  <official_title>A Phase II Study of Bendamustine, Velcade and Dexamethasone (BVD) in the Treatment of Elderly Patients (&gt;= 65 Years) With Multiple Myeloma in 1st Relapse or Refractory to 1st Line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone du Myelome</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intergroupe Francophone du Myelome</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present trial is designed as a phase II study that aims at estimating the efficacy of the
      combination of bendamustine, bortezomib and dexamethasone in relapsed/refractory multiple
      myeloma (MM). The response rate, i.e. the rate of the patients achieving a Complete Response
      or Partial Response at cycle 4, divided by the total intent to treat patient number is chosen
      as primary efficacy endpoint.

      The estimation of the efficacy rate is to be based on an explorative pilot study, since
      immediate embarking on a large-scale comparative efficacy trial would not be acceptable from
      the point of view of resources. Moreover, this would induce ethical objections, as it does
      not seem to be justifiable to expose a large number of patients to an experimental approach
      without sufficient exploratory indications of an improved risk-benefit ratio.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After relapse or after early progression on first-line treatment, the prognosis of multiple
      myeloma (MM) patients is unfavourable, and the search for new treatment regimens, including
      drugs with novel mechanisms of action is essential.

      Bendamustine and bortezomib have shown high activity boch in first-line regimens and
      pre-treated patients. The novel mechanism of action of the proteasome inhibitor and the
      non-cross resistance of bendamustine to other alkylating agents established in the first-line
      treatment of multiple myeloma seem to recommend a combination of the two drugs for salvage
      therapy (second-line regimen). Finally, the promising response data in a series of relapsing
      MM patients treated with bendamustine, bortezomib and prednisone support this assumption, as
      well as the feasibility and tolerability of the combination.

      In summary, there is some evidence for a favorable risk/benefit ratio for the combination of
      bendamustine, bortezomib and a corticoid drug, warranting the exploration in a larger,
      prospectively designed multicenter phase II study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess of the overall response rate (complete response (CR) + partial response (PR))</measure>
    <time_frame>After four 28-day consecutives cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to best response</measure>
    <time_frame>the time from treatment start to the first detection of the best response category, calculated for all patients, which are not primarily refractory</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>The time form the initial dose of chemotherapy to the time of disease progression or death, or to the date of last assessment without any such event (censored observation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>The time from baseline to the development of progressive disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>The time interval from initial dose to the date of death or last observation (censored)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of additional response</measure>
    <time_frame>Following 2 consolidation cycles and following 6 maintenance cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity/Adverse events</measure>
    <time_frame>From the time a signed and dated informed consent form is obtained until 60 days following the lase dose of study medication or until the start of a new subsequent antimyeloma therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>BVD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bendamustine, Velcade and Dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine, Velcade and Dexamethasone</intervention_name>
    <description>Bendamustine : 70 mg/m2 iv on D1 and 8, for each cycle Velcade : 1.3 mg/m2 iv on D1, 8, 15 and 22, for each cycle Dexamethasone : 20 mg/day po on D1, 8, 15 and 22, given prior to Bendamustine and Velcade</description>
    <arm_group_label>BVD</arm_group_label>
    <other_name>Robimustin : Bendamustine</other_name>
    <other_name>Velcade : Bortezomib</other_name>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic multiple myeloma (MM) patient at the time of diagnosis (but not
             necessarily at the time of relapse), according to International Myeloma Working Group
             criteria.

          -  Patient having received conventional chemotherapy in 1st line treatment because of age
             65 years or over, or younger than 65 years and ineligible to high-dose therapy plus
             stem cell transplantation.

          -  Measurable disease (≥10g/L monoclonal gammapathy and/or ≥ 200 mg/24h proteinuria or
             involved serum free light chain ≥ 100mg/L with abnormal FLC ratio &lt; 0.26 or &gt; 1.65)

          -  Patient in 1st relapse or refractory to 1st line therapy. Relapse is defined by
             M-component increase of ≥25% from baseline, in serum and/or urine (the absolute
             increase in serum must be ≥ 5 g/l - the absolute increase of BJ proteins in urine must
             be ≥200 mg/24 h). (It is recommended to treat only symptomatic or rapidly evolutive
             relapses)

          -  Life expectancy of at least 3 months

          -  ECOG performance status &lt;= 2 at study entry

          -  Laboratory test results within these ranges:

          -  Absolute neutrophil count &gt;= 1.5 x 109/L

          -  Platelet count &gt;= 100 x 109/L

          -  Serum creatinine &lt;= 250 umol/l

          -  AST (SGOT) and ALT (SGPT) &lt;= 3 x ULN

          -  Disease free of prior malignancies for &gt;= 5 years, with exception of curatively
             treated basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of the
             cervix or breast

          -  Able to adhere to the study visit schedule and other protocol requirements

          -  Using effective contraceptive methods during and for 6 months after study treatment
             (for fertile men, women of childbearing potential).

          -  Provision of informed consent.

          -  A period of at least 15 days must be respected between the last treatment of myeloma
             and the beginning of the study.

        Exclusion Criteria:

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form.

          -  Any comorbidity which places the subject at unacceptable risk if he/she were to
             participate in the study.

          -  Patients treated with high-dose therapy plus stem cell transplantation in 1st line
             therapy

          -  Any prior use of bortezomib (Velcade) or bendamustine (Ribomustin)

          -  Concurrent use of other anti-cancer agents or treatments other than those stated in
             this treatment plan

          -  Use of any other experimental drug or therapy within 28 days prior to the start of
             study treatment.

          -  Known hypersensitivity to the study drugs

          -  Positive HIV serology, positive hepatitis C serology, active infection hepatitis A,
             active infection hepatitis B.

          -  Severe cardiovascular disorders within 12 months prior to the start of study treatment
             (e.g. myocardial infarct, ischemic episodes, arrhythmias)

          -  Previous major surgery less than 30 days before start of treatment

          -  Active infection,

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe RODON, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unité Hématologie Biologique Institut Curie PARIS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cyrille HULIN, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service Hématologie Hôpitaux de Brabois VANDOEUVRE LES NANCY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Luc HAROUSSEAU, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Service Hématologie CHU Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire MATHIOT, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>IFM Hématologie Biologique Institut Curie PARIS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Odile PETILLON, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>IFM Hôpital Claude Huriez Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU, Hôpital du Bocage</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier H.Duffaut</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Cote Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz / CHU BESANCON</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Blois</city>
        <zip>41016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital A.Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre F.Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Sud Francilien</name>
      <address>
        <city>Corbeil-essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU DIJON, Hôpital Le Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Général</name>
      <address>
        <city>Dunkerque</city>
        <zip>59385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital A.Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Départemental</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Chartres</name>
      <address>
        <city>Le Coudray</city>
        <zip>28629</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Archet 1</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intitut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital St-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hopsitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier René Dubos</name>
      <address>
        <city>Pontoise</city>
        <zip>95300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Région d'Annecy</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Reims Hôpital R.Debré</name>
      <address>
        <city>Reims</city>
        <zip>51032</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpital sud</name>
      <address>
        <city>Rennes</city>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Huguenin</name>
      <address>
        <city>Saint-cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Valence</city>
        <zip>26953</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpitaux de Brabois</name>
      <address>
        <city>Vandoeuvre</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH P.Chubert</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2010</study_first_submitted>
  <study_first_submitted_qc>January 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2010</study_first_posted>
  <last_update_submitted>March 28, 2012</last_update_submitted>
  <last_update_submitted_qc>March 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2012</last_update_posted>
  <responsible_party>
    <name_title>Dr Claire Mathiot</name_title>
    <organization>Intergroupe Francophone du Myelome</organization>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Elderly patients</keyword>
  <keyword>first relapse</keyword>
  <keyword>refractory to first line therapy</keyword>
  <keyword>Bendamustine Velcade Dexamethasone Association</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

